Intellia Therapeutics price target raised to $25 from $15 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Intellia Therapeutics (NTLA) to $25 from $15 and keeps a Buy rating on the shares. The FDA signaled that Nex-Z’s clinical risk is manageable by lifting the clinical hold, but the market is still pricing in “an existential threat,” the analyst tells investors in a research note. The firm upped its probability of approval to 35% from 25%.